Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes
Yükleniyor...
Dosyalar
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
NLM (Medline)
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose: The present study aims to identify basaloid and luminal molecular groups and the p53-like sub-group, which is a sub-group of the luminal group, using a specific immunohistochemical panel and investigate human epithelial growth factor receptor 2 (HER2)/Neu and Fascin expression in these groups to analyze their relationship with clinicopathological features and prognosis in a cohort of cases with muscle-invasive urothelial bladder carcinoma (MIBC). Material and Methods: An immunohistochemical panel that included GATA-3, CK20, CD44, and CK5/6 was used to identify molecular sub-groups based on expression in 44 cases of MIBC. HER2/Neu and Fascin expression in basal, luminal, and p53-like groups and the relationship with clinicopathological features and prognosis were investigated. Results: The distribution of the molecular sub-groups determined by immunohistochemistry was as follows: 23 luminal cases (52.3%), 16 basal cases (36.4%), and 5 (11.4%) p53-like cases. There was a statistically significant difference in tumor size across the groups, with the greatest size in the p53-like group (p = 0.001). A statistically significant difference was observed in HER2/Neu expression between the molecular sub-groups (p = 0.017). Comparison of survival and HER2/Neu scores revealed shorter survival in patients with an HER2/Neu score of 3 + compared to those with scores of 0, 1+, and 2+ (p = 0.109). Fascin immunoreactivity was more common in the p53-like and basal groups compared to the luminal group (p = 0.036). Conclusion: Despite the limited number of cases in the MIBC group, our results support that HER2/Neu expression in the luminal sub-group and Fascin expression in basal and p53-like groups may be used as a negative prognostic marker. Multi-center studies that include large case series are warranted in this field.
Açıklama
Anahtar Kelimeler
Basal, bladder cancer, fascin, HER2/Neu, immunohistochemistry, luminal, p53-like, actin binding protein, carrier protein, epidermal growth factor receptor 2, fascin, protein p53, tumor marker, bladder tumor, breast tumor, female, genetics, human, metabolism, muscle, pathology, phenotype, prognosis, Biomarkers, Tumor, Breast Neoplasms, Carrier Proteins, Female, Humans, Microfilament Proteins, Muscles, Phenotype, Prognosis, Receptor, ErbB-2, Tumor Suppressor Protein p53, Urinary Bladder Neoplasms
Kaynak
Indian journal of pathology & microbiology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
65
Sayı
3
